Arshad Jamal Ansari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arshad Jamal Ansari has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Devesh Madhukar Sawant
Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Ajmer 305817, Rajasthan, India
8 shared publications Antim K. Maurya
Natural Product Chemistry and Process Development Division, CSIR-IHBT, Palampur, Himachal Pradesh 176061, India
5 shared publicationsVijai K. Agnihotri
Natural Product Chemistry and Process Development Division, CSIR-IHBT, Palampur, Himachal Pradesh 176061, India
5 shared publications- Yong Zhang
University of Southern California
4 shared publications Ashoke Sharon
Department of Chemistry, Birla Institution of Technology, Mesra, Ranchi, Jharkhand, 835215, India
3 shared publicationsGaurav Joshi
Department of Pharmaceutical Sciences, Hemvati Nandan Bahuguna Garhwal University, Srinagar 246174, India
3 shared publications
Latest Publications
- Open Access
- 21 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e18329
Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.
- 21 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e18329
Open AccessSynthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.
- Open Access
- 19 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases
Cell-secreted exosomes have been emerging as an increasingly attractive form of nanomaterials for biomedical research. Various approaches have been established to genetically modify exosomes with proteins of interest for new and/or improved functions. However, equipping exosomes with diverse non-protein biomolecules remains largely dependent on random chemical conjugation or membrane insertion, hindering the application potential of exosomes. Herein, we develop a technology for site-specific functionalization of exosome with different synthetic groups by exploiting surface-expressed CD38, an ADP-ribosyl cyclase, and its covalent inhibitor derived from nicotinamide adenine dinucleotide (NAD + ). The designed ADP-ribosyl cyclase-enabled exosomes (ARC Exos) carrying conjugated fluorescent imaging probes, small-molecule ligands, cytotoxic payloads, and bone-targeting agents are demonstrated with in vitro and/or in vivo activities and specificities. This ARC Exos-based platform provides a general approach with great versatility for chemically reprogramming exosomes.
- 19 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases
Cell-secreted exosomes have been emerging as an increasingly attractive form of nanomaterials for biomedical research. Various approaches have been established to genetically modify exosomes with proteins of interest for new and/or improved functions. However, equipping exosomes with diverse non-protein biomolecules remains largely dependent on random chemical conjugation or membrane insertion, hindering the application potential of exosomes. Herein, we develop a technology for site-specific functionalization of exosome with different synthetic groups by exploiting surface-expressed CD38, an ADP-ribosyl cyclase, and its covalent inhibitor derived from nicotinamide adenine dinucleotide (NAD + ). The designed ADP-ribosyl cyclase-enabled exosomes (ARC Exos) carrying conjugated fluorescent imaging probes, small-molecule ligands, cytotoxic payloads, and bone-targeting agents are demonstrated with in vitro and/or in vivo activities and specificities. This ARC Exos-based platform provides a general approach with great versatility for chemically reprogramming exosomes.
- Open Access
- 17 June 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 189, 118274
Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases
- 17 June 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 189, 118274
Open AccessTargeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases
- Open Access
- 30 October 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (11) , 1940-1946
Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation
Poly-ADP-ribose polymerases (PARPs) that catalyze cellular ADP-ribosylation play important roles in human health. PARP inhibitors have found success in the clinic for cancer treatment. However, isoform-specific inhibitors are needed for improved safety. Here, we report the unexpected discovery of nicotinamide mimics that block non-PARP1-catalyzed ADP-ribosylation at micromolar concentrations. These PARP1-sparing PARP inhibitors represent first-in-class probes for ADP-ribosylation, shedding light on the selective inhibition of PARPs.
- 30 October 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (11) , 1940-1946
Open AccessDiscovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation
Poly-ADP-ribose polymerases (PARPs) that catalyze cellular ADP-ribosylation play important roles in human health. PARP inhibitors have found success in the clinic for cancer treatment. However, isoform-specific inhibitors are needed for improved safety. Here, we report the unexpected discovery of nicotinamide mimics that block non-PARP1-catalyzed ADP-ribosylation at micromolar concentrations. These PARP1-sparing PARP inhibitors represent first-in-class probes for ADP-ribosylation, shedding light on the selective inhibition of PARPs.
- Open Access
- 1 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (25) , 6963-6969
An interrupted Corey–Chaykovsky reaction of designed azaarenium salts: synthesis of complex polycyclic spiro- and fused cyclopropanoids
Operationally straightforward substrate-based cyclization pathways facilitated by dimethyloxosulfonium methylide on designed enone-tethered azaarenium salts provide access to unprecedented classes of cyclopropanoids.
- 1 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (25) , 6963-6969
Open AccessAn interrupted Corey–Chaykovsky reaction of designed azaarenium salts: synthesis of complex polycyclic spiro- and fused cyclopropanoids
Operationally straightforward substrate-based cyclization pathways facilitated by dimethyloxosulfonium methylide on designed enone-tethered azaarenium salts provide access to unprecedented classes of cyclopropanoids.
- 16 May 2022
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (23) , 4746-4752
Pd-Catalysed [3 + 2]-cycloaddition towards the generation of bioactive bis-heterocycles/identification of COX-2 inhibitors via in silico analysis
Pd-catalysed [3 + 2] cycloaddition reaction of VECs and nitrile oxides to access bis-heterocycles was developed. In silico -based studies suggested interaction with COX receptors that may be corroborated biologically in the future.
- 16 May 2022
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (23) , 4746-4752
Pd-Catalysed [3 + 2]-cycloaddition towards the generation of bioactive bis-heterocycles/identification of COX-2 inhibitors via in silico analysis
Pd-catalysed [3 + 2] cycloaddition reaction of VECs and nitrile oxides to access bis-heterocycles was developed. In silico -based studies suggested interaction with COX receptors that may be corroborated biologically in the future.
- 19 October 2020
- Published by Wiley in Asian Journal of Organic Chemistry
- Vol. 9 (12) , 2136-2143
Mechanistic Investigations for the Formation of Active Hexafluoroisopropyl Benzoates Involving Aza‐Oxyallyl Cation and Anthranils
Herein, we report a multicomponent approach to access hexafluoroisopropyl activated esters using anthranil and aza‐oxyallyl cation with hexafluoroisopropyl alcohol (HFIP) under mild reaction conditions. Activated (HFIP) esters synthesized via this approach serve as an important intermediate to obtain coveted 1,4‐benzodiazepine‐3,5‐dione derivatives. The mechanism of the reaction was studied quantum mechanically using density functional theory (DFT) with functional M06‐2X and 6–31G (d, p) basis set. Different pathways were investigated. Calculated results reveal probable involvement of two mechanisms in current transformation.
- 19 October 2020
- Published by Wiley in Asian Journal of Organic Chemistry
- Vol. 9 (12) , 2136-2143
Mechanistic Investigations for the Formation of Active Hexafluoroisopropyl Benzoates Involving Aza‐Oxyallyl Cation and Anthranils
Herein, we report a multicomponent approach to access hexafluoroisopropyl activated esters using anthranil and aza‐oxyallyl cation with hexafluoroisopropyl alcohol (HFIP) under mild reaction conditions. Activated (HFIP) esters synthesized via this approach serve as an important intermediate to obtain coveted 1,4‐benzodiazepine‐3,5‐dione derivatives. The mechanism of the reaction was studied quantum mechanically using density functional theory (DFT) with functional M06‐2X and 6–31G (d, p) basis set. Different pathways were investigated. Calculated results reveal probable involvement of two mechanisms in current transformation.
- 6 March 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 56 (35) , 4804-4807
Metal free amination of congested and functionalized alkyl bromides at room temperature
Herein, we report a highly facile and unprecedented approach to synthesize congested N-(hetero)aryl amines en route to α-amino acid amides using α-bromoamides as alkylating agents under mild reaction conditions (room temperature). The involvement of aza-oxyallyl cations as alkylating agents is the hallmark of this reaction. The method was readily adapted for the rapid synthesis of coveted 1,4-benzodiazepine-3,5-diones.
- 6 March 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 56 (35) , 4804-4807
Metal free amination of congested and functionalized alkyl bromides at room temperature
Herein, we report a highly facile and unprecedented approach to synthesize congested N-(hetero)aryl amines en route to α-amino acid amides using α-bromoamides as alkylating agents under mild reaction conditions (room temperature). The involvement of aza-oxyallyl cations as alkylating agents is the hallmark of this reaction. The method was readily adapted for the rapid synthesis of coveted 1,4-benzodiazepine-3,5-diones.